Literature DB >> 20383184

Prostate cancer: utility of the risk indicator model in screening.

Stacy Loeb, William J Catalona.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 20383184      PMCID： PMC3130616          DOI： 10.1038/nrurol.2010.41

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  7 in total

1.  Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram.

Authors:  E W Steyerberg; M J Roobol; M W Kattan; T H van der Kwast; H J de Koning; F H Schröder
Journal:  J Urol       Date:  2007-01       Impact factor: 7.450

2.  Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability.

Authors:  H Ballentine Carter; Luigi Ferrucci; Anna Kettermann; Patricia Landis; E James Wright; Jonathan I Epstein; Bruce J Trock; E Jeffrey Metter
Journal:  J Natl Cancer Inst       Date:  2006-11-01       Impact factor: 13.506

3.  A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer.

Authors:  Monique J Roobol; Ewout W Steyerberg; Ries Kranse; Tineke Wolters; Roderick C N van den Bergh; Chris H Bangma; Fritz H Schröder
Journal:  Eur Urol       Date:  2009-09-01       Impact factor: 20.096

4.  Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

Authors:  A V D'Amico; R Whittington; S B Malkowicz; D Schultz; K Blank; G A Broderick; J E Tomaszewski; A A Renshaw; I Kaplan; C J Beard; A Wein
Journal:  JAMA       Date:  1998-09-16       Impact factor: 56.272

5.  A graphical device to represent the outcomes of a logistic regression analysis.

Authors:  Ries Kranse; Monique Roobol; Fritz H Schröder
Journal:  Prostate       Date:  2008-11-01       Impact factor: 4.104

6.  The Prostate Cancer Prevention Trial and European Randomized Study of Screening for Prostate Cancer risk calculators indicating a positive prostate biopsy: a comparison.

Authors:  Roderick C N van den Bergh; Monique J Roobol; Tineke Wolters; Pim J van Leeuwen; Fritz H Schröder
Journal:  BJU Int       Date:  2008-08-18       Impact factor: 5.588

7.  Can prostate specific antigen velocity thresholds decrease insignificant prostate cancer detection?

Authors:  Stacy Loeb; Kimberly A Roehl; Brian T Helfand; Donghui Kan; William J Catalona
Journal:  J Urol       Date:  2010-01       Impact factor: 7.450
  7 in total
  2 in total

1.  The C-terminal fragment of prostate-specific antigen, a 2331 Da peptide, as a new urinary pathognomonic biomarker candidate for diagnosing prostate cancer.

Authors:  Kenji Nakayama; Takahiro Inoue; Sadanori Sekiya; Naoki Terada; Yu Miyazaki; Takayuki Goto; Shigeki Kajihara; Shin-Ichiro Kawabata; Shinichi Iwamoto; Kuniko Ikawa; Junko Oosaga; Hiroaki Tsuji; Koichi Tanaka; Osamu Ogawa
Journal:  PLoS One       Date:  2014-09-18       Impact factor: 3.240

2.  Development of sarcosine quantification in urine based on enzyme-coupled colorimetric method for prostate cancer diagnosis.

Authors:  Vichanan Yamkamon; Benjarong Phakdee; Sakda Yainoy; Thummaruk Suksrichawalit; Tararat Tatanandana; Premsant Sangkum; Warawan Eiamphungporn
Journal:  EXCLI J       Date:  2018-05-17       Impact factor: 4.068
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.